Project Grant R01AR083385
Award Date
9/2/24
Completion Date
7/31/29
Dollars Obligated
$466K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $359,879 to the University of North Carolina at Chapel Hill to conduct research on the genetic basis of hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The research aims to build upon previous genome-wide association studies to identify additional genetic risk...
This $718,693 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a collaborative research project between Henry Ford Health and Michigan State University Health Sciences to conduct whole-genome sequencing analysis of Hidradenitis Suppurativa (HS). The key objectives are to: 1) Perform whole-genome sequencing analysis to identify...
This Project Grant award of $161,922 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at The Johns Hopkins University to investigate the role of gamma secretase (GS) activity and nicastrin (NCSTN) regulation in hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The research aims to define the enzymatic activity of GS and regulation of NCSTN expression in HS fibroblasts, as well as...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. This grant will fund the development and characterization of recombinant, cell-penetrating botulinum protease variants that can inhibit the release of neuropeptides and cytokines in neurons and immune cells, respectively. The goal is to create a new topical therapeutic...
This Project Grant award of $390,913, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a mechanistic investigation of the role of the protein SERPINB3 in the pathogenesis of psoriasis. The research, to be conducted by Arizona State University, aims to explore how the misprocessing of SERPINB3 may be the initiating factor in the development of psoriasis....
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on defining and treating genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatoses. The total award amount is $628,968.00 with a project period from June 20, 2025 to April 30, 2030. The awardee is The Regents of the University of California, San Francisco (UCSF), a prominent...
This federal Project Grant award of $594,600.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the instructive roles of mesenchymal proteoglycans in hair follicle morphogenesis and maintenance. The research aims to investigate 1) how proteoglycan production is controlled in dermal papilla cells, 2) the functions of proteoglycans on dermal...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a programmable siRNA-based therapeutic platform for gene silencing in the skin. The $249,000 award supports research at the University of Massachusetts Medical School to systematically evaluate the safety and efficacy of selective JAK1 silencing by therapeutic siRNA in mouse models...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $242,310 to Rockefeller University to investigate the long-term systemic consequences of type 2 skin inflammation on epithelial stem cells. The research aims to uncover how allergic type 2 inflammation impacts the functional responsiveness and epigenetic state of epithelial stem...